Cogent's Bezuclastinib Combination Therapy Shows Promise in GIST Treatment
Event summary
- Cogent Biosciences' Phase 3 PEAK trial results for bezuclastinib + sunitinib in GIST patients will be presented orally at the 2026 ASCO Annual Meeting on May 30, 2026.
- Top-line results were reported in November 2025, with an NDA submitted under the RTOR program in March 2026.
- The company plans to initiate a Phase 2 trial this quarter for first-line GIST patients with exon 9 mutations.
- Andrew J. Wagner, M.D., Ph.D., from Dana-Farber Cancer Institute, will present the data.
The big picture
Cogent's positive Phase 3 data for bezuclastinib in GIST comes at a time when precision oncology is gaining traction, with targeted therapies becoming the standard of care for genetically defined cancers. The RTOR submission indicates confidence in the data, but the competitive landscape for GIST treatments remains challenging. Success in this indication could validate Cogent's precision therapy approach and open doors to broader applications in other genetically driven diseases.
What we're watching
- Regulatory Pathway
- Whether the RTOR program will expedite the approval process for bezuclastinib in GIST.
- Clinical Expansion
- The pace at which Cogent advances the Phase 2 trial for first-line GIST patients.
- Market Positioning
- How the positive data positions bezuclastinib against existing GIST treatments.
Related topics